Cargando…

RIPK3 Contributes to Lyso-Gb3-Induced Podocyte Death

Fabry disease is a lysosomal storage disease with an X-linked heritage caused by absent or decreased activity of lysosomal enzymes named alpha-galactosidase A (α-gal A). Among the various manifestations of Fabry disease, Fabry nephropathy significantly affects patients’ morbidity and mortality. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, So-Young, Park, Samel, Lee, Seong-Woo, Lee, Ji-Hye, Lee, Eun Soo, Kim, Miri, Kim, Youngjo, Kang, Jeong Suk, Chung, Choon Hee, Moon, Jong-Seok, Lee, Eun Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911493/ https://www.ncbi.nlm.nih.gov/pubmed/33513913 http://dx.doi.org/10.3390/cells10020245

Ejemplares similares

Curcumin Blocks High Glucose-Induced Podocyte Injury via RIPK3-Dependent Pathway
por: Chung, Hyunsoo, et al.
Publicado: (2022)

Lyso-Gb3 Increases αvβ3 Integrin Gene Expression in Cultured Human Podocytes in Fabry Nephropathy
por: Trimarchi, Hernán, et al.
Publicado: (2020)

Elevated LysoGb3 Concentration in the Neuronopathic Forms of Mucopolysaccharidoses
por: Baydakova, Galina, et al.
Publicado: (2020)

Lyso-Gb3 modulates the gut microbiota and decreases butyrate production
por: Aguilera-Correa, John-Jairo, et al.
Publicado: (2019)

Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?
por: Duro, Giovanni, et al.
Publicado: (2018)

Identification of MYC as an antinecroptotic protein that stifles RIPK1–RIPK3 complex formation
por: Seong, Daehyeon, et al.
Publicado: (2020)

Publisher Correction: Lyso-Gb3 modulates the gut microbiota and decreases butyrate production
por: Aguilera-Correa, John-Jairo, et al.
Publicado: (2020)

Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease
por: Nowak, Albina, et al.
Publicado: (2022)

Elucidating the toxic effect and disease mechanisms associated with Lyso-Gb3 in Fabry disease
por: Nikolaenko, Valeria, et al.
Publicado: (2023)

Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb(3)) in Fabry Transgenic Mice and in the Plasma of Fabry Patients
por: Young-Gqamana, Brandy, et al.
Publicado: (2013)

Glucosylsphingosine (Lyso-Gb(1)): An Informative Biomarker in the Clinical Monitoring of Patients with Gaucher Disease
por: Gayed, Matthew M., et al.
Publicado: (2022)

A Rapid and Simple UHPLC-MS/MS Method for Quantification of Plasma Globotriaosylsphingosine (lyso-Gb3)
por: Perrone, Alessandro, et al.
Publicado: (2021)

Protective effects of klotho on palmitate-induced podocyte injury in diabetic nephropathy
por: Suk Kang, Jeong, et al.
Publicado: (2021)

Contribution of Glucosylsphingosine (Lyso-Gb1) to Treatment Decisions in Patients with Gaucher Disease
por: Dinur, Tama, et al.
Publicado: (2023)

Soluble klotho as a marker of renal fibrosis and podocyte injuries in human kidneys
por: Cho, Nam-Jun, et al.
Publicado: (2018)

Assessment of plasma lyso-Gb(3) for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease
por: Bichet, Daniel G., et al.
Publicado: (2020)

Insights into the Value of Lyso-Gb1 as a Predictive Biomarker in Treatment-Naïve Patients with Gaucher Disease Type 1 in the LYSO-PROOF Study
por: Curado, Filipa, et al.
Publicado: (2023)

Angiotensin II-mediated MYH9 downregulation causes structural and functional podocyte injury in diabetic kidney disease
por: Kang, Jeong Suk, et al.
Publicado: (2019)

Correction: Assessment of plasma lyso-Gb(3) for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease
por: Bichet, Daniel G., et al.
Publicado: (2020)

Impairment of Mitochondrial ATP Synthesis Induces RIPK3-dependent Necroptosis in Lung Epithelial Cells During Lung Injury by Lung Inflammation
por: Lee, Su Hwan, et al.
Publicado: (2022)

Glucosylsphingosine (lyso-Gb1) as a Biomarker for Monitoring Treated and Untreated Children with Gaucher Disease
por: Hurvitz, Noa, et al.
Publicado: (2019)

Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in Gaucher disease: a narrative review
por: Giuffrida, Gaetano, et al.
Publicado: (2023)

Nano-LC-MS/MS for Quantification of Lyso-Gb3 and Its Analogues Reveals a Useful Biomarker for Fabry Disease
por: Sueoka, Hideaki, et al.
Publicado: (2015)

The Fabry disease-associated lipid Lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain
por: Choi, L., et al.
Publicado: (2015)

Effect of Ambroxol chaperone therapy on Glucosylsphingosine (Lyso-Gb1) levels in two Canadian patients with type 3 Gaucher disease
por: Charkhand, Behshad, et al.
Publicado: (2019)

Value of Glucosylsphingosine (Lyso-Gb1) as a Biomarker in Gaucher Disease: A Systematic Literature Review
por: Revel-Vilk, Shoshana, et al.
Publicado: (2020)

Paclitaxel Ameliorates Palmitate-Induced Injury in Mouse Podocytes
por: Son, Seung Seob, et al.
Publicado: (2020)

Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis
por: Maruyama, Hiroki, et al.
Publicado: (2018)

Gaucher Disease Diagnosis Using Lyso-Gb1 on Dry Blood Spot Samples: Time to Change the Paradigm?
por: Dinur, Tama, et al.
Publicado: (2022)

Ginkgo biloba extract (GbE) enhances the anti-atherogenic effect of cilostazol by inhibiting ROS generation
por: Jung, In-Hyuk, et al.
Publicado: (2012)

Electroacupuncture at GB34 modulates neurogenesis and BDNF-ERK signaling in a mouse model of Parkinson's disease
por: Lee, Yukyoung, et al.
Publicado: (2023)

Long-Term Effect of Antibodies against Infused Alpha-Galactosidase A in Fabry Disease on Plasma and Urinary (lyso)Gb3 Reduction and Treatment Outcome
por: Rombach, Saskia M., et al.
Publicado: (2012)

Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis
por: Maruyama, Hiroki, et al.
Publicado: (2019)

Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis
por: Maruyama, Hiroki, et al.
Publicado: (2018)

Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis
por: Maruyama, Hiroki, et al.
Publicado: (2018)

Treatment Efficiency in Gaucher Patients Can Reliably Be Monitored by Quantification of Lyso-Gb1 Concentrations in Dried Blood Spots
por: Cozma, Claudia, et al.
Publicado: (2020)

A Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometric Assay for the Quantification of Fabry Disease Biomarker Globotriaosylceramide (GB3) in Fabry Model Mouse
por: Shin, Seok-Ho, et al.
Publicado: (2018)

Inhibition of Pseudomonas aeruginosa LPS‐Induced airway inflammation by RIPK3 in human airway
por: Yun, Minsu, et al.
Publicado: (2022)

Ubiquitylation of RIPK3 beyond-the-RHIM can limit RIPK3 activity and cell death
por: Frank, Daniel, et al.
Publicado: (2022)

2,8,9-Tris(2-methylpropyl)-2,5,8,9-tetraaza-1λ(5)-phosphatricyclo[3.3.3.0(1,5)]undecan-5-ium chloride dihydrate
por: Lee, Junseong, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_s1s3sp11g42e01ebdb5k664qrg